Раковая наука и терапия

Is It Possible To Reduce the Risk of Hepatocellular Carcinoma by Taking Statin in Diabeties Mellitus Patients with HBV or HCV

Abstract

Guei-Fen Chiu, Yu-Han Chang, Den-Chang Wu, Ming-Tsang Wu4 and Kun-Der Lin

Objectives: To determine the relationship between the dose effect of Statin and the risk of HCC.

Methods: This study was a case-control study. All participants were �?� 50 years of age and were diagnosed with diabetes (ICD-9250.0x 0, 205.0 × 2) and were treated with an anti-diabetic agent for at least for 3 months according to the NHID, LHID2010 (longitudinal health insurance database 2010). We captured the use of a Statin before the index date in patients with type II diabetes. Patients diagnosed with a hepatoma (ICD-9:155) were defined as the case group.

Results: The risk of hepatoma was reduced in patients with higher cumulative DDDs statin use compared to statin non-users. (HBV population: cumulative dose>298 DDDs: OR=0.41; 95% CI:0.24-0.72; HCV population: cumulative dose>205 DDDs: [OR=0.25; 95% CI: 0.13-0.48]).

Conclusion: A dose-response relationship exists between lower risk of hepatoma and higher cumulative DDDs of statin use.